Health News

FDA Expands Label for Daklinza
On February 5, 2016, FDA approved changes to the DAKLINZA(daclatasvir) label to expand the indication to include HCV genotype 1 infection and expand dosage recommendations to the following populations and to revise dosage recommendations for HCV genotype 3 subjects with compensated (Child-Pugh A) cirrhosis:
FDA OKs New Hep C Rx
The U.S. Food and Drug Administration today approved Zepatier (elbasvir and grazoprevir) with or without ribavirin for the treatment of chronic hepatitis C virus (HCV) genotypes 1 and 4 infections in adult patients.
No Shortage of Hepatitis C Treatments
In the last three years, there have been many advances in hepatitis C treatment. Hepatitis C is an infection that affects the liver and can lead to liver disease if left untreated.
Are Hep C Drugs Worth the Cost?
Newly developed drugs to treat hepatitis C infection can cost upward of $100,000 for a full course of treatment. Do the benefits of these drugs outweigh the costs?
A Potential Cure for Hep C Infection
A pill is causing quite a stir after it was suggested as a potential cure for hepatitis C.
A One-Step Test to Detect Hep C
Testing patients for hepatitis C infection might have just gotten a whole lot easier.
An Added Benefit of HIV Therapy
Hepatitis B infection can be a serious risk for patients with HIV. But there may be some good news on that front.
Hep C Type 3 Treatment Approved
The U.S. Food and Drug Administration today approved Daklinza (daclatasvir) for use with sofosbuvir to treat hepatitis C virus (HCV) genotype 3 infections.
FDA Approves Novel Hep C Rx
The U.S. Food and Drug Administration today approved Technivie (ombitasvir, paritaprevir and ritonavir) for use in combination with ribavirin for the treatment of hepatitis C virus (HCV) genotype 4 infections in patients without scarring and poor liver function (cirrhosis).
Hep C Estimates Could Be Way Off
Knowing how common a certain condition is can help prepare health care systems to treat patients. But the estimates for one disease may be way off.